FDA Approved Jakafi for Treatment of Polycythemia

December 6, 2014 11:43 AM

3 0

The largest independent specialty pharmacy in the United States, Diplomat Pharmacy Inc. has announced that the FDA approved Jakafi for treatment of Polycythemia. Jakafi is a new drug recently launched by the Incyte Corporation and is used as treatment for patients suffering of polycythemia Vera and also from high or inter-mediate risk of myelofibrosis.

The FDA approved Jakafi for treatment of polycythemia vera, a chronic bone marrow disease, in people that do not have an adequate response to hydroxyurea. Hydroxyurea is a medication that is used often to reduce the platelets and red blood cells numbers in the blood.

Read more

To category page